W
INDV icon

WealthCollab’s Indivior Pharmaceuticals INDV Stock Holding History

WealthCollab’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9K Hold
95
– – ﹤0.01% 794
2025
Q4 		$3.41K Hold
95
– – ﹤0.01% 799
2025
Q3 		$2.29K Hold
95
– – ﹤0.01% 811
2025
Q2 		$1.4K Buy
+95
New +$1.11K ﹤0.01% 859

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WealthCollab's INDV Position: Q1 2026 in Review

WealthCollab held its Indivior Pharmaceuticals (INDV) position steady in Q1 2026 at 95 shares worth $2.9K. The position accounts for ﹤0.01% of the portfolio, ranked #794.

WealthCollab first reported a position in INDV in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.41K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • WealthCollab held 95 shares of Indivior Pharmaceuticals worth $2.9K as of Q1 2026.
  • WealthCollab left its Indivior Pharmaceuticals share count unchanged in Q1 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of WealthCollab's portfolio in Q1 2026, its #794 holding.
  • WealthCollab first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • WealthCollab's Indivior Pharmaceuticals position peaked at $3.41K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on WealthCollab's 13F filing for Q1 2026, filed 13 May 2026.